FOXO4-DRI vs Urolithin A
A side-by-side research comparison of FOXO4-DRI and Urolithin A across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | FOXO4-DRI | Urolithin A |
|---|---|---|
| Full name | FOXO4-D-Retro-Inverso Peptide (Senolytic) | Urolithin A (Mitophagy Activator) |
| Category | Anti-Aging | Anti-Aging |
| Status | Research compound | Dietary compound (clinical studies) |
| Mechanism | Competitively disrupts FOXO4 sequestration of p53 in senescent cells, releasing p53 to trigger intrinsic apoptosis selectively in cells relying on this survival mechanism. | Stimulates mitophagy - the selective recycling of damaged mitochondria - improving mitochondrial quality and energy efficiency in muscle and other tissues. |
| Molecular weight | ~4,500 Da | 228.20 Da |
| Half-life | 12-24 hours (D-amino acid stability) | Several hours |
| Bioavailability | Moderate (SubQ) | Oral; bypasses the need for the gut bacteria many people lack |
| Typical dose | 5-10 mg/kg (animal studies) | 500-1000 mg per day |
| Frequency | 3x per week for 3 weeks | Once daily |
| Route | Subcutaneous | Oral |
FOXO4-DRI reported benefits
- Selective senescent cell elimination
- Potential aging reversal
- Improved tissue function
- Reduced inflammatory burden
- Hair regrowth (mice)
Urolithin A reported benefits
- Improves mitochondrial function (mitophagy)
- Increased muscle endurance
- Cellular energy support
- Studied for healthy aging
Related comparisons
Research and educational reference only. Not medical advice.